Volume 104, Issue 9 pp. 2664-2675
COMMENTARY

Oral Solid Dosage Form Disintegration Testing — The Forgotten Test

Jozef Al-Gousous

Jozef Al-Gousous

Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, Mainz, D-55128 Germany

Search for more papers by this author
Peter Langguth

Corresponding Author

Peter Langguth

Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, Mainz, D-55128 Germany

Telephone: +49-6131-392-5746; Fax: +49-6131-392-5021; E-mail: [email protected]Search for more papers by this author
First published: 24 December 2014
Citations: 6

Abstract

Since its inception in the 1930s, disintegration testing has become an important quality control (QC) test in pharmaceutical industry, and disintegration test procedures for various dosage forms have been described by the different pharmacopoeias, with harmonization among them still not quite complete. However, because of the fact that complete disintegration does not necessarily imply complete dissolution, much more research has been focused on dissolution rather than on disintegration testing. Nevertheless, owing to its simplicity, disintegration testing seems to be an attractive replacement to dissolution testing as recognized by the International Conference on Harmonization guidelines, in some cases. Therefore, with proper research being carried out to overcome the associated challenges, the full potential of disintegration testing could be tapped saving considerable efforts allocated to QC testing and quality assurance. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2664–2675, 2015

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.